We studied the effect of chenodeoxycholic acid in 17 patients with cerebrotendinous xanthomatosis. Before treatment, all subjects were symptomatic, with Achilles tendon xanthomas (in 15 of 17), cataracts (in 12 of 17), dementia (in 13 of 17), pyramidal-tract signs (in all 17), cerebellar dysfunction (in 13 of 17), mild peripheral neuropathy (in 7 of 17), electroencephalographic abnormalities (in 10 of 13), and abnormal cerebral computerized axial tomographic scans (in 10 of 12). After at least one year of chenodeoxycholic acid treatment (750 mg per day), dementia cleared in 10 subjects, and pyramidal and cerebellar signs disappeared in 5 and improved in another 8. Peripheral neuropathy was no longer detected in six. The electroencephalogram became normal in five and showed fewer abnormalities in another three subjects. Cerebral computerized axial tomographic scans improved in seven patients; the changes included the disappearance of a cerebellar xanthoma in one case. Concomitantly, mean plasma cholestanol levels declined threefold, and abnormal bile acid synthesis was suppressed. We conclude that long-term therapy with chenodeoxycholic acid may correct the biochemical abnormalities and arrest and possibly reverse the progression of cerebrotendinous xanthomatosis.
This article has been cited by other articles:
Szlago, M., Gallus, G. N., Schenone, A., Patino, M. E., Sfaelo, Z., Rufa, A., Da Pozzo, P., Cardaioli, E., Dotti, M. T., Federico, A.
(2008). THE FIRST CEREBROTENDINOUS XANTHOMATOSIS FAMILY FROM ARGENTINA: A NEW MUTATION IN CYP27A1 GENE. Neurology
70: 402-404
[Full Text]
Panzenboeck, U., Andersson, U., Hansson, M., Sattler, W., Meaney, S., Bjorkhem, I.
(2007). On the mechanism of cerebral accumulation of cholestanol in patients with cerebrotendinous xanthomatosis. J. Lipid Res.
48: 1167-1174
[Abstract][Full Text]
Pikuleva, I. A.
(2006). CHOLESTEROL-METABOLIZING CYTOCHROMES P450. Drug Metab. Dispos.
34: 513-520
[Abstract][Full Text]
Lorincz, M. T., Rainier, S., Thomas, D., Fink, J. K.
(2005). Cerebrotendinous Xanthomatosis: Possible Higher Prevalence Than Previously Recognized. Arch Neurol
62: 1459-1463
[Abstract][Full Text]
Honda, A., Salen, G., Matsuzaki, Y., Batta, A. K., Xu, G., Hirayama, T., Tint, G. S., Doy, M., Shefer, S.
(2005). Disrupted coordinate regulation of farnesoid X receptor target genes in a patient with cerebrotendinous xanthomatosis. J. Lipid Res.
46: 287-296
[Abstract][Full Text]
Castelnovo, G, Jomir, L, Bouly, S
(2003). Cerebrotendinous xanthomatosis. J. Neurol. Neurosurg. Psychiatry
74: 1335-1335
[Full Text]
Federico, A., Dotti, M. T.
(2003). Cerebrotendinous Xanthomatosis: Clinical Manifestations, Diagnostic Criteria, Pathogenesis, and Therapy. J Child Neurol
18: 633-638
[Abstract]
Inglese, M., DeStefano, N., Pagani, E., Dotti, M. T., Comi, G., Federico, A., Filippi, M.
(2003). Quantification of Brain Damage in Cerebrotendinous Xanthomatosis with Magnetization Transfer MR Imaging. Am. J. Neuroradiol.
24: 495-500
[Abstract][Full Text]
Moghadasian, M. H., Salen, G., Frohlich, J. J., Scudamore, C. H.
(2002). Cerebrotendinous Xanthomatosis: A Rare Disease With Diverse Manifestations. Arch Neurol
59: 527-529
[Abstract][Full Text]
Samenuk, P., Koffman, B. M., Salen, G.
(2001). Chenodeoxycholic treatment of cerebrotendinous xanthomatosis. Neurology
56: 695-696
[Full Text]
Lee, M.-H., Hazard, S., Carpten, J. D., Yi, S., Cohen, J., Gerhardt, G. T., Salen, G., Patel, S. B.
(2001). Fine-mapping, mutation analyses, and structural mapping of cerebrotendinous xanthomatosis in U.S. pedigrees. J. Lipid Res.
42: 159-169
[Abstract][Full Text]
De Stefano, N., Dotti, M. T., Mortilla, M., Federico, A.
(2001). Magnetic resonance imaging and spectroscopic changes in brains of patients with cerebrotendinous xanthomatosis. Brain
124: 121-131
[Abstract][Full Text]
Barkhof, F., Verrips, A., Wesseling, P., van der Knaap, M. S., van Engelen, B. G. M., Gabreëls, F. J. M., Keyser, A., Wevers, R. A., Valk, J.
(2000). Cerebrotendinous Xanthomatosis: The Spectrum of Imaging Findings and the Correlation with Neuropathologic Findings. Radiology
217: 869-876
[Abstract][Full Text]
Verrips, A., Hoefsloot, L. H., Steenbergen, G. C. H., Theelen, J. P., Wevers, R. A., Gabreels, F. J. M., van Engelen, B. G. M., van den Heuvel, L. P. W. J.
(2000). Clinical and molecular genetic characteristics of patients with cerebrotendinous xanthomatosis. Brain
123: 908-919
[Abstract][Full Text]
Verrips, A., van Engelen, B. G. M., Wevers, R. A., van Geel, B. M., Cruysberg, J. R. M., van den Heuvel, L. P. W. J., Keyser, A., Gabreels, F. J. M.
(2000). Presence of Diarrhea and Absence of Tendon Xanthomas in Patients With Cerebrotendinous Xanthomatosis. Arch Neurol
57: 520-524
[Abstract][Full Text]
Wakamatsu, N., Hayashi, M., Kawai, H., Kondo, H., Gotoda, Y., Nishida, Y., Kondo, R., Tsuji, S., Matsumoto, T.
(1999). Mutations producing premature termination of translation and an amino acid substitution in the sterol 27-hydroxylase gene cause cerebrotendinous xanthomatosis associated with parkinsonism. J. Neurol. Neurosurg. Psychiatry
67: 195-198
[Abstract][Full Text]
Verrips, A., Lycklama a Nijeholt, G. J., Barkhof, F., Van Engelen, B. G. M., Wesseling, P., Luyten, J. A. F. M., Wevers, R. A., Stam, J., Wokke, J. H. J., van den Heuvel, L. P. W. J., Keyser, A., Gabreels, F. J. M.
(1999). Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. Brain
122: 1589-1595
[Abstract][Full Text]
